McKesson Signs Agreement to Buy Precision Medicine Group for About $2.25 Billion

A Distributor Buys the Company That Tests the Drugs It Ships

McKesson already ships nearly a third of the prescription drugs sold in the United States. It already owns a network of more than 700 cancer clinics that treat about 1.5 million patients a year^[13]. On August 25, 2026, it agreed to buy the company that helps drugmakers run the clinical trials and market launches for those same drugs^[1][2].

The price is about $2.25 billion in cash^[1][2]. The target is Precision Medicine Group, a privately held firm based in Bethesda, Maryland, with more than 1,000 employees spread across North America, Europe and Asia-Pacific^[6]. Once the deal closes, Precision will report into McKesson's Oncology & Multispecialty division^[2].

Nobody disputes those facts. What people disagree about is what they add up to. Is this a drug distributor filling a gap in its services lineup, or a company quietly buying every link in the chain between a new cancer drug and the patient who takes it?

What Precision Actually Sells

Precision Medicine Group is what's called a contract research organization, or CRO. Drugmakers hire firms like this to run the outside work of getting a drug approved and sold: finding patients for clinical trials, running lab tests that show which patients respond to a drug, and building the sales and pricing strategy for launch^[1][3].

Big pharmaceutical companies used to do all of this in-house. Increasingly they don't. They hire specialists instead, because trials have gotten more complex and drugmakers want fewer vendors to manage^[3][4]. Precision built its business by offering trial operations, biomarker testing, and market-access consulting under one roof^[1][3].

That's the appeal to McKesson. A drug company running an oncology trial today might work with one firm to find eligible patients, a separate lab for testing, and a third consultant for launch pricing. McKesson is betting that folding those pieces into one shop, and pairing that shop with its own distribution network, saves time and money for the drugmakers who are its customers^[1][3].

The Case for a Bolt-On

McKesson's own explanation is straightforward. Distribution is high volume and thin margin: moving pills is a business worth hundreds of billions of dollars a year, but the profit on each shipment is small. McKesson has spent years shifting toward higher-margin businesses like specialty and oncology services, where it can charge more for expertise rather than just moving boxes^[4].

Wall Street read the deal that way too. Analysts at Leerink Partners and J.P. Morgan called it a strategic fit and a modest bet given McKesson's size, though they noted investors will want proof the new business can actually scale^[9]. McKesson's stock rose 3.25% on the day of the announcement^[5].

That stock move is worth a caveat. The same day, McKesson also reported quarterly earnings that beat Wall Street's forecasts and raised its guidance for the year^[5]. The 3.25% gain reflects all three pieces of news together, not a clean verdict on the acquisition alone^[5].

The company selling Precision has its own logic. Blackstone-led funds took a controlling stake in Precision back in November 2020, in a deal reported at the time to be worth roughly $2.3 billion^[6][7][14]. A $2.25 billion sale price six years later is close to flat in raw dollars, and lower once inflation is factored in — a detail that undercuts any reading of this sale as a windfall for its private-equity owners^[14].

Why Critics Call It Self-Dealing

Here's the tension underneath the deal. McKesson is one of three companies, along with Cencora and Cardinal Health, that together handle more than 90% of the prescription drugs distributed in the United States^[10]. All three have spent recent years buying into cancer care instead of just shipping drugs to it^[10].

McKesson already owns The US Oncology Network, bought in 2010 for about $2.2 billion, and expanded it further with a 2024 deal for Florida Cancer Specialists, bringing the network past 700 locations and roughly 1.5 million patients treated a year^[13]. So McKesson doesn't just distribute the cancer drugs. It also owns many of the practices that prescribe them.

Anti-monopoly advocates argue that structure creates a conflict most people would recognize by instinct. If one company distributes a drug, owns the clinic that prescribes it, and — after this deal — runs the trials that get it approved and the strategy that launches it, the checks that would normally sit between those roles start to disappear. Monique Whitney, executive director of Pharmacists United for Truth and Transparency, put it this way about McKesson's earlier oncology purchases: "A drug wholesaler owning a physician practice is the very definition of self-dealing. This will allow McKesson to basically sell to itself"^[10].

That argument already reached the Federal Trade Commission once. In a letter dated September 26, 2024, the American Economic Liberties Project urged the FTC to block McKesson's and Cardinal Health's oncology acquisitions^[10][11]. Senator Elizabeth Warren separately wrote to the FTC chair raising the same concern^[12]. Those deals went through anyway^[13], which sets a real precedent: a services deal like this one, without a direct overlap in any single market, is likely to be an even harder case to challenge than the practice deals critics already lost.

Two Very Different Audiences for the Same News

Coverage of the deal split largely along who each outlet imagined was reading. Pharma trade press wrote for the industry it covers: Fierce Pharma's headline said McKesson would "snap up" Precision Medicine Group, deal-desk language that treats this as corporate strategy with no mention of the antitrust history^[4]. Retail-investor sites like Investing.com framed success purely in stock-price terms, with the only named risk being whether the promised synergies show up^[8].

Health-policy trade press told a different story. Fierce Healthcare's coverage of the earlier oncology fight led with the advocates' demand that the FTC intervene, using language like "big-ticket acquisitions" that carries a mild edge^[10]. Oncology News Central went further, headlining a piece "Two Massive Oncology Acquisitions Should Be Blocked by Regulators, Critics Say" — properly attributed to critics, but with the verdict sitting right in the headline^[10].

Overseas trade press covered it as neither a Wall Street story nor a Washington story. UK-based Pharmaceutical Technology framed the deal as a shake-up of the global contract-research market, with rival CRO firms and trial sponsors as the parties affected — not U.S. patients or U.S. antitrust law^[3]. That's a reminder that the same $2.25 billion transaction reads as three separate stories depending on which readers an outlet is writing for.

What Happens Next Isn't Public Yet

The deal still needs to clear customary closing conditions, including regulatory review, and McKesson hasn't announced a closing date^[1]. As of August 31, 2026, no agency has publicly signaled a challenge to this specific transaction^[1].

Whether that stays true is the open question. The FTC let McKesson's earlier moves into cancer practices go through despite formal objections^[10][13]. Whether it treats a research-and-commercialization purchase the same way — or whether critics manage to make the self-dealing argument land this time — will only be visible once regulators actually weigh in.